Replies to post #191691 on Avid Bioservices Inc (CDMO)

[biopharm]

Looking at Dr. Martin Edelman for now...but first everyone should know, if one did not truly know... that Dr. Martin Edelman was a Bavituximab supporter and not saying he is not no longer, but we will soon find out.

Dr. Martin Edelman: "I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations," said Martin J. Edelman, M.D., Professor of Medicine at the University of Maryland Greenebaum Cancer Center

Dr. Edelman, Martin - post Part I

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92210261

Dr. Edelman, Martin - post Part II

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92435317&txt2find=martin|edelman

Dr. Edelman has had ties to working and collaborating and dozens of disclosures all leading back to Bristol Myers Squibb and it is now clear that SOMETHING forced Dr. Edelman into changing his mind to back off of working with Peregrine Pharmaceuticals and back into the Bristol Myers Squibb scene.... what would that be? This may be just one of many more puzzle pieces that will blow the lid off of how corrupt certain Big Pharma can be

Some don't think that it will go public and some are just collecting so much info that there will much more than enough info to make solid connections

https://clinicaltrials.gov/ct2/show/NCT00037089

[biopharm]

Since Sunrise final data coming soon... Lots of work to do ...

Dr. Edelman Martin : Part III .... Big Bavi supporter now leaves Univ. of New Mexico and heads back to MD

Quote:
David E. Gerber 1,
1. The University of Texas Southwestern Medical Center, Dallas, TX;

Joseph Shan 2,
2. Peregrine Pharmaceuticals, Inc., Tustin, CA;

Ulrich Keilholz 3,
3. Charité Comprehensive Cancer Center, Berlin, Germany;

David R. Spigel 4,
4. Sarah Cannon Research Institute, Nashville, TN;

Leora Horn 5,
5. Vanderbilt-Ingram Cancer Center, Nashville, TN;

Rebecca Suk Heist 6,
6. Massachusetts General Hospital, Boston, MA;

Rachel E. Sanborn 7,
7. Providence Portland Medical Center, Portland, OR;

Paul N. Mainwaring 8,
8. ICON Cancer Care, South Brisbane, Australia;

Chandra Prakash Belani 9,
9. Penn State Hershey Cancer Institute, Hershey, PA;

Martin J. Edelman 10;
10. University of New Mexico Cancer Center, Albuquerque, NM

http://www.peregrineinc.com/images/stories/pdfs/sunrise_2014.pdf

[biopharm]

Dr. Martin Edelman: Part III .... Big Bavi supporter now leaves Univ. of New Mexico and heads back to MD

Dr Martin Edelman went on record saying he was looking forward to working with Bavituximab as he went to UNM and left around June 2014 after just 1 year ....and who shows up there at UNM?

Dr Olivier Rixe soon after Dr Edelman in July 2014
https://www.linkedin.com/in/olivier-rixe-3a45653b

....and now Dr Rixe working / PI with a PS Targeting drug from Bexion....another strange twist to point out but Dr Yanis Boumber not no more at UNM??!!

One should read the Dr Martin Edelman posts part I II III
..etc and realize how he went to UNM and lured back and it is as if some groups do not like when anyone of value would be about to give PS Targeting more value because all three of these docs now just bouncing around....all strings pulled by ??? to avoid PS Targeting advancements ??

---------------

United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Teresa L Stewart, MS,CRCP 505-925-0367 [e-mail]
Principal Investigator: Yanis Boumber, MD, PhD
Principal Investigator: Olivier Rixe, MD, PhD
https://www.clinicaltrials.gov/show/NCT02859857

https://www.linkedin.com/in/yanis-boumber-8a87042
----------------

Even more bizarre like being poached back and forth is the other PI Dr Yanis Boumber listed above at UNM says below he left UNM for Fox Chase ( where Dr Martin Edelman just landed recently...)

--------------

October 26th, 2015
Lung Cancer Specialist Brings New Treatments and Hope to New Mexicans
http://cancer.unm.edu/newsroom/lung-cancer-specialist-brings-new-treatments-and-hope-to-new-mexicans/

------------------

Therapeutics Program
OCTOBER 3, 2016
Yanis Boumber, MD, PhD
Yanis Boumber, MD, PhD
PHILADELPHIA (October 3, 2016) – Yanis Boumber, MD, PhD, will join the Department of Thoracic Medical Oncology and the Molecular Therapeutics Program at Fox Chase Cancer Center starting Oct. 3.

Boumber first joined Fox Chase’s Department of Medical Oncology in 2013 and now returns to Fox Chase from the University of New Mexico Comprehensive Cancer Center.

https://www.foxchase.org/news/2016_10_03-Yanis-Boumber-returns-dept-thoracic-surgery